Ibrutinib Combination Therapy for CLL Patients Shows Promise

Here’s a breakdown of the data provided in the text:

Research Article:

* Title: Investigating the addition of ianalumab (VAY736) to ibrutinib in patients with chronic lymphocytic leukemia (CLL) on ibrutinib therapy: results from a phase Ib study
* Journal: Clinical Cancer Research

* Publication Year: 2025
* DOI: 10.1158/1078-0432.CCR-25-0210
* Link: https://dx.doi.org/10.1158/1078-0432.CCR-25-0210

Source of Information:

* provided by: american association for Cancer Research
* Link to AACR: http://www.aacr.org/default.aspx

News Article Information (for citation):

* Title: Combination treatment may help cut lifelong ibrutinib for chronic lymphocytic leukemia patients
* Date Published: November 6, 2025
* Date accessed: November 6, 2025 (implied from “retrieved 6 Novem”)

In essence, this text describes a news article reporting on a research study published in Clinical Cancer Research about a potential new treatment combination for chronic lymphocytic leukemia (CLL).